Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US.
The FDA approved medications are indicated as an addition to diet and exercise for the treatment of type 2 diabetes.
Takeda Pharmaceuticals USA diabetes and obesity marketing senior director Jennifer Greeby said, “The availability of NESINA, KAZANO and OSENI marks an important milestone in Takeda’s commitment to patients living with type 2 diabetes, and provides new options for physicians.”
The dipeptidyl peptidase-4 inhibitor (DPP-4i), NESINA, is designed to slow the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Combination of alogliptin with metformin HCl, KAZANO, is an anti-diabetes medication formulated in a single tablet in addition to single tablet regeime OSENI that combines alogliptin with the thiazolidinedione (TZD) pioglitazone.
